[
  {
    "ts": null,
    "headline": "Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade)",
    "summary": "Moderna, Inc. stock is up ~60% YTD on cancer vaccine trial data, 2026 readouts, and 2025 financials. Click for this updated look at MRNA stock prospects.",
    "url": "https://finnhub.io/api/news?id=e5be86e568c54ea77965da66629737f2e763f011a62bd56277759861fd9e0977",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769790248,
      "headline": "Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade)",
      "id": 138309874,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2233333501/image_2233333501.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Moderna, Inc. stock is up ~60% YTD on cancer vaccine trial data, 2026 readouts, and 2025 financials. Click for this updated look at MRNA stock prospects.",
      "url": "https://finnhub.io/api/news?id=e5be86e568c54ea77965da66629737f2e763f011a62bd56277759861fd9e0977"
    }
  },
  {
    "ts": null,
    "headline": "Dr. David Berman to Join Moderna as Chief Development Officer",
    "summary": "CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer, beginning March 2, 2026. He will serve on Moderna's ...",
    "url": "https://finnhub.io/api/news?id=d685fb415102346775b14f96ac78ea5f9b1149f31355f46f98f6142e11219ea1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769776200,
      "headline": "Dr. David Berman to Join Moderna as Chief Development Officer",
      "id": 138305546,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer, beginning March 2, 2026. He will serve on Moderna's ...",
      "url": "https://finnhub.io/api/news?id=d685fb415102346775b14f96ac78ea5f9b1149f31355f46f98f6142e11219ea1"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?",
    "summary": "Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and MRNA and see which is better for you.",
    "url": "https://finnhub.io/api/news?id=efe578fb6afc0a27df0a3b9c00d68ee5b14efefe359b92b65a401f46df986530",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769767768,
      "headline": "Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?",
      "id": 138305889,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1017623360/image_1017623360.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and MRNA and see which is better for you.",
      "url": "https://finnhub.io/api/news?id=efe578fb6afc0a27df0a3b9c00d68ee5b14efefe359b92b65a401f46df986530"
    }
  }
]